HEMOBIOTECH, INC.·4

Dec 17, 4:19 PM ET

Nino Ghassan 4

4 · HEMOBIOTECH, INC. · Filed Dec 17, 2010

Insider Transaction Report

Form 4
Period: 2010-12-13
Nino Ghassan
Director10% Owner
Transactions
  • Award

    Options to Purchase Common Stock

    2009-10-31+21,000108,000 total
    Exercise: $0.28From: 2009-10-31Exp: 2014-10-31Common Stock (21,000 underlying)
  • Award

    Options to Purchase Common Stock

    2010-03-26+11,000144,000 total
    Exercise: $0.56From: 2010-03-26Exp: 2015-03-26Common Stock (11,000 underlying)
  • Award

    Options to Purchase Common Stock

    2010-09-24+7,000171,000 total
    Exercise: $0.33From: 2010-09-24Exp: 2015-09-24Common Stock (7,000 underlying)
  • Award

    Options to Purchase Common Stock

    2010-09-24+18,000189,000 total
    Exercise: $0.33From: 2010-09-24Exp: 2015-09-24Common Stock (18,000 underlying)
  • Award

    Options to Purchase Common Stock

    2009-09-25+7,00087,000 total
    Exercise: $0.30From: 2009-09-25Exp: 2014-09-25Common Stock (7,000 underlying)
  • Award

    Options to Purchase Common Stock

    2009-12-24+7,000115,000 total
    Exercise: $0.55From: 2009-12-24Exp: 2014-12-24Common Stock (7,000 underlying)
  • Award

    Options to Purchase Common Stock

    2009-12-31+11,000126,000 total
    Exercise: $0.34From: 2009-12-31Exp: 2014-12-31Common Stock (11,000 underlying)
  • Award

    Options to Purchase Common Stock

    2010-03-26+7,000133,000 total
    Exercise: $0.56From: 2010-03-26Exp: 2015-03-26Common Stock (7,000 underlying)
  • Award

    Options to Purchase Common Stock

    2010-06-25+7,000151,000 total
    Exercise: $0.44From: 2010-06-25Exp: 2015-06-25Common Stock (7,000 underlying)
  • Award

    Options to Purchase Common Stock

    2010-06-25+13,000164,000 total
    Exercise: $0.44From: 2010-06-25Exp: 2015-06-25Common Stock (13,000 underlying)
Footnotes (12)
  • [F1]From October 31, 2009 through September 30, 2010, the board of directors received additional options in lieu of their quarterly compensation. These options are immediately vested and exercisable upon issuance.
  • [F10]The Options to Purchase Common Stock were granted on June 25, 2010. All Options are immediately vested and exercisable upon issuance.
  • [F11]The Options to Purchase Common Stock were granted on September 24, 2010. All Options are immediately vested and exercisable upon issuance.
  • [F12]The Options to Purchase Common Stock were granted on September 24, 2010. All Options are immediately vested and exercisable upon issuance.
  • [F2]On November 18, 2010, the board of directors of HemoBioTech, Inc. agreed to reprice all options to $.25.
  • [F3]The Options to Purchase Common Stock were granted on September 25, 2009. All Options are immediately vested and exercisable upon issuance.
  • [F4]The Options to Purchase Common Stock were granted on October 31, 2009. All Options are immediately vested and exercisable upon issuance.
  • [F5]The Options to Purchase Common Stock were granted on December 24, 2009. All Options are immediately vested and exercisable upon issuance.
  • [F6]The Options to Purchase Common Stock were granted on December 31, 2009. All Options are immediately vested and exercisable upon issuance.
  • [F7]The Options to Purchase Common Stock were granted on March 26, 2010. All Options are immediately vested and exercisable upon issuance.
  • [F8]The Options to Purchase Common Stock were granted on March 26, 2010. All Options are immediately vested and exercisable upon issuance.
  • [F9]The Options to Purchase Common Stock were granted on June 25, 2010. All Options are immediately vested and exercisable upon issuance.

Documents

1 file
  • 4
    doc1.xmlPrimary

    FORM 4